Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presentation ACC 2019

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presenter: Marco Valgimigli

March 18, 2019

News Opinion Editor's Corner ACC 2019

Live From New Orleans: Days 2 and 3 at ACC 2019

Shelley Wood

March 18, 2019

Presentation ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

Presenter: Deepak L. Bhatt

March 18, 2019

Video

» Interview

ACC 2019: TREAT Trial: Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

March 18, 2019

Video

» Interview

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

March 18, 2019

Advertisement

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Live From New Orleans: Days 2 and 3 at ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

ACC 2019: TREAT Trial: Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content